Maria Braoudaki
Overview
Explore the profile of Maria Braoudaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohamed A, Abaza T, Youssef Y, Rady M, Fahmy S, Kamel R, et al.
Nanoscale Adv
. 2025 Jan;
7(4):934-962.
PMID: 39823046
Extracellular vesicles (EVs) are emerging as viable tools in cancer treatment due to their ability to carry a wide range of theranostic activities. This review summarizes different forms of EVs...
2.
Ahmad M, Braoudaki M, Siddiqui S
PLoS One
. 2024 Sep;
19(9):e0311212.
PMID: 39348343
Colorectal cancer (CRC) has become a significant global health concern and ranks among the leading causes of morbidity and mortality worldwide. Due to its malignant nature, current immunotherapeutic treatments are...
3.
Mustafov D, Siddiqui S, Kukol A, Lambrou G, Shagufta , Ahmad I, et al.
ACS Omega
. 2024 Jul;
9(29):31789-31802.
PMID: 39072119
Glioblastoma (GB) is an aggressive brain malignancy characterized by its invasive nature. Current treatment has limited effectiveness, resulting in poor patients' prognoses. β-Amino carbonyl (β-AC) compounds have gained attention due...
4.
Assal R, Elemam N, Mekky R, Attia A, Soliman A, Gomaa A, et al.
Transl Oncol
. 2024 Apr;
45:101961.
PMID: 38631259
Tumor microenvironment is an intricate web of stromal and immune cells creating an immune suppressive cordon around the tumor. In hepatocellular carcinoma (HCC), Tumor microenvironment is a formidable barrier towards...
5.
Orton S, Karkia R, Mustafov D, Gharanei S, Braoudaki M, Filipe A, et al.
Cancers (Basel)
. 2024 Feb;
16(3).
PMID: 38339334
Background: Protein Tyrosine Phosphatase Receptor Type D (PTPRD) is involved in the regulation of cell growth, differentiation, and oncogenic transformation, as well as in brain development. PTPRD also mediates the...
6.
Ogbodo A, Mustafov D, Arora M, Lambrou G, Braoudaki M, Siddiqui S
Heliyon
. 2024 Jan;
10(2):e24286.
PMID: 38268823
Siglecs belong to a family of immune regulatory receptors predominantly found on hematopoietic cells. They interact with Sia, resulting in the activation or inhibition of the immune response. Previous reports...
7.
Elemam N, Mekky R, Rashid G, Braoudaki M, Youness R
Expert Rev Mol Med
. 2024 Jan;
26:e1.
PMID: 38186186
The host immune system status remains an unresolved mystery among several malignancies. An immune-compromised state or smart immune-surveillance tactics orchestrated by cancer cells are the primary cause of cancer invasion...
8.
Sarridou D, Mouratoglou S, Mitchell J, Cox F, Boutou A, Braoudaki M, et al.
J Pers Med
. 2023 Dec;
13(12).
PMID: 38138898
(1) Background: Thoracic epidural analgesia is considered the gold standard in post-operative pain management following thoracic surgery. This study was designed to explore the safety of thoracic epidural analgesia and...
9.
Youness R, Mohamed A, Efthimiadou E, Mekky R, Braoudaki M, Fahmy S
ACS Omega
. 2023 Dec;
8(47):44424-44436.
PMID: 38046305
To provide precise medical regimens, photonics technologies have been involved in the field of nanomedicine. Phototriggered liposomes have been cast as promising nanosystems that achieve controlled release of payloads in...
10.
Ahmad M, Braoudaki M, Patel H, Ahmad I, Shagufta , Siddiqui S
Front Immunol
. 2023 Oct;
14:1254911.
PMID: 37869015
Siglecs are well known immunotherapeutic targets in cancer. Current checkpoint inhibitors have exhibited limited efficacy, prompting a need for novel therapeutics for targets such as Siglec-15. Presently, small molecule inhibitors...